Zhao Zhenwen, Xu Yan
Department of Obstetrics and Gynecology, Indiana University Cancer Center, Indiana University School of Medicine, USA.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3739-42. doi: 10.1016/j.jchromb.2009.08.032. Epub 2009 Aug 27.
The levels of lysophosphatidic acid (LPA) or lysophosphatidylcholine (LPC) in plasma have been shown to be markers for several human diseases, including cancers. Here we show that the presence of LPC or other lysophospholipids (LPLs) in lipids extracted from biological samples affects accurate measurement of endogenous LPA in biological samples. We report for the first time the artificial conversion of LPC and lysophosphatidylserine (LPS) to LPA at the ion source of electrospray ionization tandem mass spectrometry (ESI-MS/MS). To avoid the interference of LPC with the quantification of LPA, a method based on high-performance liquid chromatography (HPLC) separation of LPA from LPC has been developed.
血浆中溶血磷脂酸(LPA)或溶血磷脂酰胆碱(LPC)的水平已被证明是包括癌症在内的多种人类疾病的标志物。在这里,我们表明,从生物样品中提取的脂质中存在LPC或其他溶血磷脂(LPL)会影响生物样品中内源性LPA的准确测量。我们首次报告了在电喷雾电离串联质谱(ESI-MS/MS)的离子源处LPC和溶血磷脂酰丝氨酸(LPS)人工转化为LPA的情况。为避免LPC对LPA定量的干扰,已开发出一种基于高效液相色谱(HPLC)从LPC中分离LPA的方法。